- NVP-AEW541
-
- $34.00 / 1mg
-
2026-04-22
- CAS:475489-16-8
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
- AVP-AEW541
-
- $2.00 / 1KG
-
2020-01-09
- CAS:475489-16-8
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: ask
|
| | AVP-AEW541 Basic information |
| Product Name: | AVP-AEW541 | | Synonyms: | NVP-AEW541,AEW541,AEW-541;AEW541;NVP AEW541;CS-470;AVP-AEW541;NVP-AEW541;AEW-541;NVP-AEW541(AEW541);[7-[cis-3-[(Azetidin-1-yl)methyl]cyclobutyl]-5-(3-benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine | | CAS: | 475489-16-8 | | MF: | C27H29N5O | | MW: | 439.55 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 475489-16-8.mol |  |
| | AVP-AEW541 Chemical Properties |
| Melting point | 145℃ | | Boiling point | 669.0±55.0 °C(Predicted) | | density | 1.33 | | storage temp. | 2-8°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | pka | 9.59±0.10(Predicted) | | form | powder | | color | white to beige | | InChIKey | AECDBHGVIIRMOI-GRGXKFILSA-N | | SMILES | C1=NC(N)=C2C(C3=CC=CC(OCC4=CC=CC=C4)=C3)=CN([C@@H]3C[C@H](CN4CCC4)C3)C2=N1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | AVP-AEW541 Usage And Synthesis |
| Uses | NVP-AEW541 is insulin-like growth factor I receptor (IGF-IR) inhibitor. | | Biological Activity | nvp-aew541 is a novel, potent and selective inhibitor of igf-ir kinase with ic50 value of 0.086 μm [1].nvp-aew541 is a pyrrolo(2,3-d) pyrimidine derivative. it has been reported to abolish igf-i-induced igf-ir autophosphorylation and to block the igf-ir signaling pathway mainly in ecc-1 and uspc-1 cancer cells. also in these cell lines, nvp-aew541 has been shown to change the igf-i induced cell cycle and to lead apoptotic cell death as well as exhibit antiproliferative effects [2]. in addition, it is observed that nvp-aew541 can induce radiosensitization in pten wild-type cell lines [3]. | | Biochem/physiol Actions | NVP-AEW541 is a reversible, ATP-competitive, orally available insulin-like growth factor-I receptor (IGF-IR, IGF-1R) inhibitor that, despite its equipotency against recombinant kinase domains of insulin receptor (InsR) and IGF-IR in cell-free kinase assays (IC50 = 140 & 150 nM, respectively), exhibits high selectivity toward cellular autophosphorylation of endogenous full-length IGF-1R (IC50 = 86 nM) over InsR (IC50 = 2.3 μM), HER1, PDGFR, c-Kit, and Bcr-Abl p210 (IC50 >5 μM). AEW541 effectively inhibits IGF-IR-mediated signaling and cancer survival (IC50 = 105 nM/MCF-7 soft agar growth, 1.64 μM/NWT-21 proliferation) in cultures and tumor growth in vivo (20 to 50 mg/kg twice daily p.o.; NWT-21 fibrosarcoma & TC-71 musculoskeletal sarcoma xenografts in mice). | | in vivo | Oral administration of NVP-AEW541 (20, 30, or 50 mg/kg) results in abrogation of basal and IGF-I-induced receptor, and PKB and MAPK phosphorylation in the NWT-21 tumor xenograft[1]. NVP-AEW541 is administered by oral gavage [50 mg/kg in 0.2 mL of 25 mM L-(+)-tartaric acid] twice a day for 14 consecutive days. The control group is similarly treated with 0.2 mL carrier [25 mM L-(+)-tartaric acid] twice a day. Tumor volume and animal weight are measured thrice a week till the end of the treatment. At that time, animals are sacrificed and tumors are collected and formalin fixed for histologic and immunohistochemical analyses. In both cases, NVP-AEW541 treatment causes tumor shrinkage that reached the statistical significance (P=0.0156 and P=0.0111 for HTLA-230 and SK-N-BE2c, respectively)[2]. | | target | IGF-IR kinase | | references | [1] carlos garc a-echeverr a, mark a. pearson, andreas marti, thomas meyer, juergen mestan, johann zimmermann, jiaping gao, josef brueggen, hans-georg capraro, robert cozens, dean b. evans, doriano fabbro, pascal furet, diana graus porta, janis liebetanz, georg martiny-baron, stephan ruetz, and francesco hofmann. in vivo antitumor activity of nvp-aew541—a novel, potent, and selective inhibitor of the igf-ir kinase. cancer cell.2004 mar (5):231-239.
[2] zohar attias-geva, itay bentov, ami fishman, haim werner, ilan bruchim. insulin-like growth factor-i receptor inhibition by speci c tyrosine kinase inhibitor nvp-aew541 in endometrioid and serous papillary endometrial cancer cell lines. gynecologic oncology. 2011 feb (121):383-389.
[3] sofie f. isebaert, johannes v. swinnen, william h. mcbride, and karin m. haustermans. insulin-like growth factor–type 1 receptor inhibitor nvp-aew541 enhances radiosensitivity of pten wild-type but not pten-deficient human prostate cancer cells. international journal of radiation oncology biology physics. 2011 (81):239-247. |
| | AVP-AEW541 Preparation Products And Raw materials |
|